200 related articles for article (PubMed ID: 33681680)
1. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
Eksteen B; Bowlus CL; Montano-Loza AJ; Lefebvre E; Fischer L; Vig P; Martins EB; Ahmad J; Yimam KK; Pockros PJ; Feld JJ; Minuk G; Levy C
Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
3. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
4. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
6. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
7. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
de Vries EM; Wang J; Leeflang MM; Boonstra K; Weersma RK; Beuers UH; Geskus RB; Ponsioen CY
Liver Int; 2016 Dec; 36(12):1867-1875. PubMed ID: 26945698
[TBL] [Abstract][Full Text] [Related]
8. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis.
Liu X; Wang H; Liu X; Bridle K; Crawford D; Liang X
Pharmacol Ther; 2022 Sep; 237():108163. PubMed ID: 35271884
[TBL] [Abstract][Full Text] [Related]
10. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
12. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis.
Rupp C; Rössler A; Halibasic E; Sauer P; Weiss KH; Friedrich K; Wannhoff A; Stiehl A; Stremmel W; Trauner M; Gotthardt DN
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1292-301. PubMed ID: 25316001
[TBL] [Abstract][Full Text] [Related]
13. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
[TBL] [Abstract][Full Text] [Related]
14. Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol.
Arndtz K; Corrigan M; Rowe A; Kirkham A; Barton D; Fox RP; Llewellyn L; Athwal A; Wilkhu M; Chen YY; Weston C; Desai A; Adams DH; Hirschfield GM;
BMJ Open; 2017 Jul; 7(6):e015081. PubMed ID: 28674140
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.
Hirschfield GM; Gershwin ME; Strauss R; Mayo MJ; Levy C; Zou B; Johanns J; Nnane IP; Dasgupta B; Li K; Selmi C; Marschall HU; Jones D; Lindor K;
Hepatology; 2016 Jul; 64(1):189-99. PubMed ID: 26597786
[TBL] [Abstract][Full Text] [Related]
16. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
[TBL] [Abstract][Full Text] [Related]
17. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
18. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.
Trivedi PJ; Muir AJ; Levy C; Bowlus CL; Manns MP; Lu X; Crans G; Chung C; Subramanian GM; Myers RP; Goodman Z; Chalasani N; Vierling JM; Guha IN; Hirschfield GM
Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1248-1257. PubMed ID: 32707342
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial.
Allegretti JR; Kassam Z; Carrellas M; Mullish BH; Marchesi JR; Pechlivanis A; Smith M; Gerardin Y; Timberlake S; Pratt DS; Korzenik JR
Am J Gastroenterol; 2019 Jul; 114(7):1071-1079. PubMed ID: 30730351
[TBL] [Abstract][Full Text] [Related]
20. Short-term prognostic factors for primary sclerosing cholangitis.
Watanabe T; Hirano K; Tada M; Isayama H; Mizuno S; Arizumi T; Toda N; Sugawara Y; Kokudo N; Koike K
J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
